Kidswell Bio Sees Stable Revenue Growth Through Biosimilar Business

TOKYO, Jun 30 (Pulse News Wire) – Kidswell Bio Corporation (4584.T) reported stable revenue growth driven by its biosimilar business, projecting continued expansion through five additional product launches. The company’s capital base was bolstered by a syndicated loan agreement worth ¥2.500 billion secured in November 2025.

In the fiscal year ending March 31, 2026, Kidswell Bio achieved a lower net profit of 287,653 due to increased research and development expenses and higher manufacturing costs amid a weaker yen environment. However, the company expects to achieve operating profitability in fiscal 2026, buoyed by recent price adjustments and cost reduction measures.

Kidswell Bio also highlighted progress in its cell therapy division, aiming to advance clinical trials for pediatric conditions such as cerebral palsy. The company plans to collaborate with international partners to expedite regulatory approvals and secure funding for future projects.